CD19 is expressed on B-lineage cells and follicular dendritic cells and plays a key role in B cell malignancies and autoimmune diseases. Thus, it has been considered as potential target for several monoclonal antibodies (mAbs). For decades, chemotherapy has been known as one of the major antitumor therapies eradicating high proliferative tumor cells. But, anti-CD19 mAbs developed for treating CD19-positive lymphomas and autoimmune diseases would rank among the most novel area of research and development in the pharmaceutical industry. Moreover, several anti-CD19 mAbs are currently being tested in various clinical trials and this review provides an overview of the research accomplished so far.
about 2500 new patients are diagnosed annually; and 80% of these patients are B-lineage acute lymphoblastic leukemia (B-ALL) (1) . In western countries, high incidence rates of non-Hodgkin's lymphoma (NHL) have been reported, and most of NHL subtypes are more prevalent among men than women (3) . The fifth most common cancer in the United States is NHL and >66,000 patients have been diagnosed with NHL in 2008 (4) . NHL is accounting for about 4% of all cancer diagnoses in incidence and deaths annually (5) . CD19 is a 95-kDa transmembrane glycoprotein which belongs to the immunoglobulin (Ig) superfamily and can act as a central positive response regulator in B cells (6, 7) . The CD19 has been expressed on the surface of leukemia cells in > 90% of cases with acute lymphoblastic leukemia (ALL). Moreover, it can be expressed on tumor cells of cases with both B-cell NHL and chronic lymphocytic leukemia (CLL).
Thus, CD19 antigen is an ideal target for immunotherapy of B-cell malignancies (8, 9) .
CD19 can act as a B cell co-receptor in conjunction with both CD21 and CD81 (10) . Genetic studies show that CD19 has a role in keeping a balance between immunity and autoimmunity (10) . Table 1) ( Fig. 1, 2 ). 
Anti

SGN-CD19A
Since CD19 has been expressed in most B-cell 
Conclusion
The CD19 
